Sir, Methodological remarks concerning the recent metaanalysis on the effect of intravitral bevacizumab in central serous chorioretinopathy
We appreciate the interest of Sergentanis and Chatziralli in our published manuscript, 'Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review.' 1 They have addressed methodological issues concerning metaanalysis because the SD of difference was not provided in the manuscript.
We absolutely agree that it would have been more meaningful meta-analysis if we contacted the authors of each study, asking them to calculate de novo the difference as Sergentanis and Chatziralli have rightly pointed out. Alternatively, Hedges g formula for pooled SD was used to estimate difference SD. And then, paired SD was calculated, as follows, pooled SD × sqrt(2 × 1 − r)).
Although our meta-analysis failed to verify the positive effect of IVB in CSC, the outcome of this treatment is still unknown owing to many limitations, such as small sample sizes, clinical heterogeneity, and methodology. Therefore, further investigation including more studies with larger scales and better methodologies will help to clarify the uncertain relationship between CSC and IVB. Five of our six patients were phakic, and underwent routine phacoemulsification surgery, with insertion of a custom-made Ophtec 0.0D black polycarbonate Ani II ('no hole') IOL into the capsular bag. This lens takes 12-14 weeks to manufacture, and technical specifications are shown in Figure 1 . Its 9-mm optic diameter allows implantation in the capsular bag, and limits side illumination in scotopic conditions. However, as it is not foldable, implantation requires a proportionately larger corneal incision, which could potentially prolong postoperative recovery and increase the risk of future infection and globe rupture.
Whilst we have not formally tested for its near-infrared (NIR) properties, other opaque polycarbonate IOLs in use, such as Ophtec 'pupil occluder' iris claw IOLs, have been shown to be NIR-blocking, thereby providing total light occlusion and minimising the risk of treatment failure. 1, 2 Clinically, all five patients had good resolution of intractable diplopia, albeit with variable light perception. The absolute occlusion with consequent symptomatic reduction of field resulted in explantation of the opaque IOL in one patient. This highlights the importance of considering loss of visual field with complete occlusion, and subsequent poor adaptation to monocular vision.
One patient had known Type II diabetes mellitus. Implantation of opaque IOLs in diabetics may be considered a relative contraindication, 3 and has not previously been described in the literature to our knowledge. Systemic conditions like diabetes tend to cause bilateral symmetrical ocular pathology. 4 In the authors' opinion, regular fundus surveillance of the fellow eye provides a reasonable proxy that predicts development of diabetic eye disease in the occluded eye. However, we concur that higher risk patients may benefit from longer-term follow-up with posterior segment imaging including optical coherence tomography, for example, those with choroidal naevi, suspicious discs, or lattice degeneration. We thank Professor MacEwen and coauthors 1 for responding to our letter describing the factors influencing primary black intraocular lens (IOL) selection. 2 They present the first study describing the clinical outcomes following primary implantation of a large (47 mm optic) black IOL within the capsular bag. The Ophtec Black Ani II IOL (Ophtec BV, Groningen, The Netherlands) is a novel device produced from a material that is identical to the Artisan 201 iris-claw IOL, which has been proven to be occlusive to near infra-red (NIR) light. 3 This series adds to the growing experience with black IOL implantation, and several observations warrant further comment.
The mechanism of light perception following black IOL implantation is a curious phenomenon and its identification is critical to minimize the risk of treatment failure. 4, 5 High rates of postoperative satisfaction are reported in patients with NIR-transmitting black IOLs, 6 despite near universal postoperative light perception. 5 We have suggested previously that trans-optical NIR light transmission across NIR-transmitting black IOLs may underlie intractable ghosting and treatment failure. 4, 5 Such symptoms are extinguished by secondary NIR-blocking Ophtec black iris-claw IOL implantation. 4, 7 Postoperative light perception in this series suggests para-optical light leakage despite a 9 mm occlusive optic, exceeding the scotopic pupil diameter. It is unlikely that formed, foveal images would result as a consequence: perceptions of 'ghosting' following Ophtec Ani II Black IOL implantation are unlikely.
Numerous black IOLs are available for clinical use, each with specific dimensions and properties that must be tailored to lens status/pupil size and the risk of retinal or optic nerve disease in each individual patient. 2 We have recently described ultra-widefield imaging in a patient with a NIR-transmitting black IOL using the Heidelberg Spectralis Scanning Laser Ophthalmoscope (Heidelberg Engineering, Heidelberg, Germany). This novel discovery may drive primary implantation of NIR-transmitting black IOLs to achieve a balance of efficacy and safetypermitting detection of retinal and optic nerve pathology across the life of the implant.
All black IOLs are likely to alleviate symptoms in patients with intractable diplopia and represent valid treatment modalities. However, it is essential that both patient and surgeon are informed of the risks of treatment failure and the possibility of ultra-widefield retinal imaging when a primary black IOL is selected.
